Some inhalers have been claimed to give better deposition, resulting in higher ecacy. In a previous study we did not ®nd any evidence of dierent potency of salbutamol given either via pMDI or Turbuhaler
Introduction
Salbutamol is a relative selective b 2 -receptor agonist, which was developed in the 1960s and ®rst marketed, in pressurized metered dose inhalers (pMDI) for local airway treatment. Since its introduction, extensive clinical studies have established the ecacy and safety of salbutamol delivered via the pMDI in the treatment of reversible obstructive disease. The pMDI has become the most popular and well-established way of delivering asthma medications to the lung, available in more than 90 countries. The reasons for the popularity of the pMDI have been its safety, portability, low cost and relative ease of use.
Although experienced pMDI users ®nd it relatively easy to use, some patients do have diculty in co-ordinating inspiration with inhalation, especially children and the elderly. This problem can to some degree be overcome by the use of spacers or breath-actuated powder inhalers.
Several dierent multiple dose powder inhalers have been introduced, including Turbuhaler 1 , Diskhaler 2 and Diskus, all of which are more or less dependent upon the patient achieving enough inspiratory eort to aerosolize the powder. The short acting b 2 -agonist terbutaline, and the corticosteroid budesonide, have been available in the Turbuhaler for a number of years and clinical studies have demonstrated equivalent, or even improved ecacy of these two drugs when delivered via pMDI as compared with Turbuhaler (1±5).
Most recently, salbutamol has become available in the Turbuhaler. Some studies, comparing the ecacy and safety of salbutamol given via Turbuhaler or pMDI have been presented. One of these recent studies suggests that when salbutamol is given via the Turbuhaler, only half the dose is required compared to when the drug is given by the pMDI (6) . In contrast to this study, our group has recently not been able to document any dierence in the bronchodilatory eect of salbutamol given either via Turbuhaler or pMDI (7) .
The Diskus is a new multiple powder inhaler, and clinical studies have demonstrated equivalent ecacy and safety when salbutamol is delivered via Diskus or Diskhaler. No data have been presented, comparing directly the safety and ecacy of salbutamol given via the Diskus or Turbuhaler.
The aim of the present study was to evaluate whether any dierences in the topical or systemic eects of salbutamol are evident when the drug is given as the same cumulative doses via Diskus or Turbuhaler.
Patients and methods
The study was performed in accordance with the principles stated in the Declaration of Helsinki, and was approved by the Ethics Committee of GoÈ teborg and the Swedish Drug Agency (Uppsala, Sweden). Furthermore, Good Clinical Trial Practice principles were applied, and the study was monitored by the sponsor (Glaxo Wellcome).
PATIENTS
Twenty-®ve adult patients (13 women), non-smokers, all with reversible air¯ow obstruction, were included. The mean age was 54 years (31±71), mean height 171 cm, and mean weight 72 kg. All patients were using inhaled glucocorticoids regularly, and short-acting b 2 -agonists p.r.n. (as needed). The patients were permitted to use inhaled corticosteroids (up to 1000 mg b.d.), sodium cromoglycate, nedocromil sodium and antihistamines, provided that the dose was constant for 4 weeks prior to visit 1 and remained constant during the trial.
Regarding b 2 -agonists, they were not allowed to take long-acting b 2 -agonists for 12 h and short-acting for 6 h prior to each clinic visit.
STUDY DESIGN
The study was designed as a randomized, double-blind, double-dummy, cross-over study to measure the topical and systemic eects in cumulative doses of salbutamol delivered by the Turbuhaler compared with the Diskus inhaler. Topical eects were assessed by measurement of FEV 1 and the systemic eects by serum potassium, heart rate, systolic and diastolic blood pressure. The same equipment (Vitalograph Compact, Vitalograph, Birmingham, U. K.) was used at all four clinic visits. The device was calibrated every morning. The highest of three technically acceptable measurements of FEV 1 was recorded in the Case Report Form.
At the pre-study visit, eligibility was assessed, which was followed 36 h±10 days later by three study visits (spaced 36 h±10 days apart). Finally, a post-study check was performed to complete the study.
At the pre-study screen, patients received 200 mg salbutamol (given by pMDI, Ventoline) followed 30 min later by 1600 mg salbutamol. The improvement seen should be at least 10% 15 min after 200 mg salbutamol, followed by another at least 50% increase of the eect observed after the lower dose.
The patients were not allowed to take an inhaled shortacting b 2 -agonist 6 h, long-acting b 2 -agonist 12 h, or an oral/sustained-release b 2 -agonist 24 h prior to pre-study day, or on the three study days. Theofyllin, oral corticosteroids or leucotriene synthesis blockers/receptor antagonists were not permitted during the conduct of the study or for the 4 weeks prior to visit 1.
On the three study days, each patient were given the following treatments in a randomized order: (a) salbutamol via Turbuhaler and placebo via Diskus or (b) salbutamol via Diskus and placebo via Turbuhaler or (c) placebo via Turbuhaler and Diskus.
Salbutamol was given in cumulative doses at approximately 30-min intervals (time=0, 30, 60, 90 and 120 min). The doses were 200, 200, 400, 800 and 1600 mg, resulting in cumulative doses of 200, 400, 800, 1600 and 3200 mg. The nominal dose per actuation was 100 mg from the Turbuhaler and 200 mg from the Diskus (2+2+4+8+16=32 inhalations via the Diskus and twice as many via the Turbuhaler per day). During the placebo day, exactly the same protocol was followed.
Blood samples for potassium was taken prior to the cumulative design regimen (baseline). After that, blood samples for potassium, blood pressure and FEV 1 measurements were taken 20±25 min after each cumulative dose. Heart rate was measured by taking pulse at the level of arteria radialis.
STATISTICAL METHODS
Pre-study power calculation gave an estimate that 24 patients would give 80% power to show equivalence of the treatments. Retrospective analysis show that the equivalence region (95% con®dence intervals) for any time point is always within 0.12 l for FEV 1 . The data obtained 20 min after each cumulative dose was averaged. The baseline value obtained prior to dosing was used as the value for a zero cumulative dose. Each of the variables (FEV 1 , heart rate and plasma potassium) were summarized in three ways:
. the mean values obtained after cumulative dose;
. area under the response time curve; . the slope from linear regression of the response against cumulative dose of each treatment (logged data).
Comparison of mean values at nominal time points or after speci®ed cumulative doses was performed by analysis of covariance using SAS proc GLM. The model included terms for patient, visit (i.e. period), baseline (pre-dosing) level, as well as treatment group. Estimates of the dierence between treatments, Diskus vs. turbuhaler, Diskus vs. placebo, Turbuhaler vs. placebo were calculated together with 95% con®dence intervals.
Comparison of mean area under the response-time curve (AUC) and the mean slope of regression of response on (log-) cumulative dose (slope) for each individual patient were carried out using the same procedure as above, though with a change of response variable (AUC or SLOPE) as appropriate.
Results
Twenty-®ve patients were included in the study and all patients completed the study. Salbutamol given either by Turbuhaler or Diskus caused signi®cant and dose-related improvement in FEV 1 (Fig. 1) . Mean FEV 1 20 min after the end of dosing (cumulative dose of 3200 mg), was 2Á50 l with Turbuhaler, 2Á46 l with Diskus and 2Á11 l with placebo. These values correspond to a percentage change from baseline of 24Á6%, 20Á5% and 3Á2% with Turbuhaler, Diskus and placebo respectively. After correction for baseline (pre-dosing) dierences, the percentage dierence between Diskus and Turbuhaler was 71.8% (P=0Á2). Comparing Diskus vs. placebo, the dierence was 16Á3% (P<0Á001) and when comparing Turbuhaler vs. placebo, the dierence was 18Á5% (P<0.001). The 95% con®dence intervals were 74Á7 to +1Á8% for the comparison between Diskus and Turbuhaler. Looking at all time points throughout the observation period, the maximal 95% con®dence intervals between treatments are 5Á5%, which equates to a maximal treatment dierence of 0Á12 l.
The average AUC dierence over the interval (t=0± t=140; baseline to 3200 mg) between salbutamol Turbuhaler and Diskus was calculated, and equalled to 70Á02 l (CI: 70Á09±0Á05 l). Comparison of average regression slopes over the dosing interval showed similar results (data not shown). With salbutamol Turbuhaler, FEV 1 increased by 0Á07 l for each doubling dose, with salbutamol Diskus this increase was 0Á06 l, and on placebo 0Á02 l. The dierence between active treatments corrected for baseline dierences was 0Á009 l per doubling dose.
There was no tendency for dierence in the induced changes in S-potassium (Fig. 2) , in heart rate (Fig. 3) or diastolic blood pressure, and after total cumulative dosing, these variable were all within the de®ned region for equivalence comparing the two active treatments (95% con®dence intervals for the true dierence).
Discussion
In their eect on FEV 1 , this study clearly demonstrates the equivalence of delivery of salbutamol in a doubling dose schedule via either Turbuhaler or Diskus. In addition, it demonstrates that both treatments show a marked bene®t compared to placebo. Likewise, eects on systemic parameters, heart rate and plasma potassium, are similar with either device.
The Turbuhaler has been suggested to improve lung deposition of inhaled drugs vs. several other inhalers (1, 8) , but no direct comparison of Turbuhaler versus Diskus has been reported. This dierence in lung deposition has been suggested to improve the ecacy of terbutaline and budesonide given by the Turbuhaler vs. their corresponding pMDI (1, 4, 5) . Some studies have also argued that salbutamol Turbuhaler is more ecacious than salbutamol pMDI (6,10±12). However, one weakness of these studies is that the drugs were not compared on equal mg doses. Also, in the study by LoÈ fdahl (6), the observed dierences in FEV 1 between the lowest and highest dose of salbutamol was quite small, amounting to a mean of 0Á15 l suggesting a quite shallow dose±response curve in the studied patients. In a more recent study, we have been unable to detect any numeric dierences in the improvement in FEV 1 between salbutamol given by the Turbuhaler and pMDI (7), which others also have been unable to detect when evaluating eects of salbutamol on methacholine responsiveness (9) .
In the present study, we have been unable to detect any dierences in potency of salbutamol given by Turbuhaler vs. Diskus. Numerically, the dierences between the devices amounted to approximately 0Á04 l, in favour of the Turbuhaler (D0Á08 l), which is far from statistically signi®cant, and not likely to be of clinical importance. Furthermore, no dierences in systemic side-eects were detected, again arguing against clinical dierences in deposition and systemic absorption of these drugs. This is quite important, since the Turbuhaler has been suggested to give more peripheral deposition, which hypothetically could result in more prominent side-eects, because of more systemic absorption from peripheral airways and lung tissue. Thus, the improved peripheral deposition of bronchodilators given by the Turbuhaler does not seem to lead to improved clinical ecacy, and does not aect the therapeutic ratio.
The dose response eect between the lowest and highest dose of salbutamol was quite high in the present study, amounting to 0Á29 l, showing that a dose-related eect of salbutamol was present in the studied patients. This is likely to be due to our selection of patients, i.e. needing to show a dose-related bronchodilation at inclusion. Many bronchodilator studies are unable to show dose-related eects of cumulative doses of drugs. We therefore suggest that including patients with step-wise improvement in FEV 1 , within the doses studied in a randomized stage of the study, increases the possibility of producing data with dose-related eects.
We conclude that no or very small dierences in potency and ecacy between salbutamol Turbuhaler and salbutamol Diskus are present in asthmatic patients. More importantly, the dierences in therapeutic ratio of these treatments are minimal, or non-existent.
